20 March 2023
The Evaluation and Learning Office (ELO) of the Global Fund, with guidance and oversight by its Independent Evaluation Panel (IEP), will commission an end-term evaluation of the Global Fund’s 2017-2022 Strategy, referred to as the Strategic Review 2023 (SR2023). This is a cyclical evaluation that occurs at the end of each Global Fund Strategy period.
The SR2023 will provide an independent appraisal of progress made on the commitments reflected in the Global Fund Strategy (2017-2022); it will examine the extent to which the objectives of the 2017-2022 Strategy were achieved and identify enabling factors that facilitated achievements as well as hindering factors that limited success. In addition, it will examine progress of the 2017-2022 Strategy against the globally recognized OECD-DAC evaluation criteria of relevance, coherence, effectiveness, efficiency, impact and sustainability. SR2023’s design and approach will emphasize utility, independence and quality of the evaluation process.
SR2023 will focus on three key objectives:
SR2023 plays an important role in promoting utilization of evidence and ongoing learning. Recommendations from the evaluation of the 2017-2022 Strategy will inform ongoing implementation of the 2023-2028 Global Fund Strategy and planning for grant cycle 8.
The Global Fund’s independent evaluation function is tasked to improve and strengthen accountability, evidence-based decision making and greater learning from evaluation evidence. Independent evaluation is delivered by the newly established Evaluation and Learning Office (ELO), and the Independent Evaluation Panel (IEP), an advisory group independent from the Secretariat and accountable to the Board through the Strategy Committee.
In November 2016, the Board approved the Global Fund Strategy 2017-2022 (Investing to End Epidemics). The four strategic objectives of the Global Fund Strategy 2017-2022 are: